Journal Article

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Khachatryan, Naira, Furin, Jennifer, Kalon, Stobdan, Isaakidis, Petros, Ferlazzo, Gabriella, Hewison, Catherine, Jonckheere, Sylvie, Hughes, Jennifer, Mohr, Erika, Egazaryan, Lusine, Shroufi, Amir, De Avezedo, Virginia, Cox, Helen, Laxmeshwar, Chinmay

2018

Overview

Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa. We retrospectively analysed a cohort of all patients who received 6–12 months of oral bedaquiline and delamanid in combination (400 mg bedaquiline once per day for 2 weeks, then 200 mg bedaquiline three times per week and 100 mg delamanid twice per day) in MSF-supported projects. We report serious adverse events, QTc corrected using the Fridericia formula (QTcF) interval data, and culture conversion data during the first 6 months of treatment. Between Jan 1, 2016, and Aug 31, 2016, 28 patients (median age 32·5 years [IQR 28·5–40·5], 17 men) were included in the analysis. 11 (39%) of 28 patients were HIV-positive. 24 patients (86%) had isolates resistant to fluoroquinolones; 14 patients (50%) had extensively drug-resistant tuberculosis. No patient had an increase of more than 500 ms in their QTcF interval. Four patients (14%) had six instances of QTcF increase of more than 60 ms from baseline but none permanently discontinued the drugs. 16 serious adverse events were reported in seven patients. Of 23 individuals with positive baseline cultures, 17 (74%) converted to negative by month 6 of treatment. Use of the bedaquiline and delamanid combination appears to reveal no additive or synergistic QTcF-prolonging effects. Access to bedaquiline and delamanid in combination should be expanded for people with few treatment options while awaiting the results of formal clinical trials. Médecins Sans Frontières (MSF).

• Publisher: Elsevier Ltd,Elsevier B.V,Elsevier Limited
• Subject: Adult / Analysis / Antitubercular Agents - therapeutic use / Armenia - epidemiology / Arrhythmias, Cardiac - chemically induced / Clinical trials / Cohort analysis / Cohort Studies / Diarylquinolines - administration & dosage / Diarylquinolines - adverse effects / Diarylquinolines - therapeutic use / Drug dosages / Drug resistance / Drug resistance in microorganisms / Drug therapy / Drug Therapy, Combination / Drugs / FDA approval / Fluoroquinolones / HIV Infections - complications / Humans / India - epidemiology / Infectious diseases / Medical research / Multidrug resistance / Nitroimidazoles - administration & dosage / Nitroimidazoles - adverse effects / Nitroimidazoles - therapeutic use / Oxazoles - administration & dosage / Oxazoles - adverse effects / Oxazoles - therapeutic use / Patients / Psychosis / Retrospective Studies / Safety / South Africa - epidemiology / Studies / Tuberculosis / Tuberculosis, Multidrug-Resistant - complications / Tuberculosis, Multidrug-Resistant - drug therapy / Tuberculosis, Multidrug-Resistant - epidemiology